8-K current report · filed Sep 17, 2026

ACCENDRA HEALTH INC/VA/ (ACH) 8-K Current Report: September 17, 2026

Item 5.02Item 8.01Item EX-99.1Item 7.01ACH overview

Short answer

ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Kenneth Gardner-Smith named CEO, succeeding retiring Edward Pesicka in early Q4 2026.

ACCENDRA HEALTH INC/VA/ 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Kenneth Gardner-Smith named CEO, succeeding retiring Edward Pesicka in early Q4 2026
  • Pesicka remains advisor during transition, then retires from the Board
  • Gardner-Smith retains Board and Executive Committee roles as non-independent director
  • CEO compensation includes $1M salary, 130% target bonus, and $6M annual equity award
  • Additional incentives include $650K sign-on bonus and $2M cash-settled stock appreciation rights

Item 7.01 · Regulation FD Disclosure

  • Planned appointment of Gardner-Smith as President and Chief Executive Officer
  • Scott Lloyd designated Chief Commercial Officer
  • Leadership changes may reshape corporate strategy and commercial execution
  • Press release dated September 17, 2026 provides appointment details

Item 8.01 · Other Events

  • Scott Lloyd appointed Chief Commercial Officer effective October 5, 2026
  • New role consolidates commercial strategy, sales, and provider and payor partnerships
  • Lloyd brings nephrology strategy and durable medical equipment experience
  • Appointment supports growth focus as Accendra scales its pure-play home-based care model

Item EX-99.1 · Exhibit EX-99.1

  • Kenneth Gardner-Smith to become President and CEO early Q4 2026, succeeding retiring CEO Edward Pesicka
  • Gardner-Smith’s board tenure since March 2022 supports continuity while bringing healthcare operating leadership from Veritas and DaVita
  • Strategy emphasis: higher-margin growth categories, operating efficiency, and investment in Accendra’s pure-play home-based care platform
  • Scott Lloyd appointed Chief Commercial Officer effective October 5, consolidating sales, commercial strategy, and provider-payor partnerships
  • Pesicka to retire from the board but remain an advisor, reducing transition-disruption risk during leadership handoff

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ACCENDRA HEALTH INC/VA/ 8-K filings

Get the next ACH 8-K as it lands

Follow ACH for push alerts, or ask the research agent what this filing means.